CN103562403A8 - 识别肿瘤起始细胞的抗体和抗原及其应用 - Google Patents

识别肿瘤起始细胞的抗体和抗原及其应用 Download PDF

Info

Publication number
CN103562403A8
CN103562403A8 CN201280010033.3A CN201280010033A CN103562403A8 CN 103562403 A8 CN103562403 A8 CN 103562403A8 CN 201280010033 A CN201280010033 A CN 201280010033A CN 103562403 A8 CN103562403 A8 CN 103562403A8
Authority
CN
China
Prior art keywords
antigen
application
initiator cell
tumour
cacna2d1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201280010033.3A
Other languages
English (en)
Other versions
CN103562403A (zh
CN103562403B (zh
Inventor
张志谦
赵威
王力民
韩海勃
刑宝才
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Institute for Cancer Research
Original Assignee
Beijing Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Institute for Cancer Research filed Critical Beijing Institute for Cancer Research
Priority to CN201280010033.3A priority Critical patent/CN103562403B/zh
Publication of CN103562403A publication Critical patent/CN103562403A/zh
Publication of CN103562403A8 publication Critical patent/CN103562403A8/zh
Application granted granted Critical
Publication of CN103562403B publication Critical patent/CN103562403B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

本发明公开了寻找、鉴别或确认肿瘤起始细胞的标志物CACNA2D1的方法，所述方法包括使用复发性肿瘤来源并富含肿瘤起始细胞的HEP-12细胞来免疫动物的步骤。本发明还公开了特异性识别CACNA2D1的单克隆抗体或其抗原结合片段，以及用于治疗或预防肿瘤或与CACNA2D1相关的疾病或病症的应用。
CN201280010033.3A 2011-02-22 2012-02-22 一个识别肿瘤起始细胞的抗体和抗原及其应用 Active CN103562403B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280010033.3A CN103562403B (zh) 2011-02-22 2012-02-22 一个识别肿瘤起始细胞的抗体和抗原及其应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201110042166.6 2011-02-22
CN2011100421666 2011-02-22
CN2011100421666A CN102251013A (zh) 2011-02-22 2011-02-22 一个识别肿瘤起始细胞的抗体和抗原及其应用
CN201280010033.3A CN103562403B (zh) 2011-02-22 2012-02-22 一个识别肿瘤起始细胞的抗体和抗原及其应用
PCT/CN2012/000227 WO2012113266A1 (zh) 2011-02-22 2012-02-22 识别肿瘤起始细胞的抗体和抗原及其应用

Publications (3)

Publication Number Publication Date
CN103562403A CN103562403A (zh) 2014-02-05
CN103562403A8 true CN103562403A8 (zh) 2018-01-26
CN103562403B CN103562403B (zh) 2018-11-16

Family

ID=44978581

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011100421666A Pending CN102251013A (zh) 2011-02-22 2011-02-22 一个识别肿瘤起始细胞的抗体和抗原及其应用
CN201280010033.3A Active CN103562403B (zh) 2011-02-22 2012-02-22 一个识别肿瘤起始细胞的抗体和抗原及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011100421666A Pending CN102251013A (zh) 2011-02-22 2011-02-22 一个识别肿瘤起始细胞的抗体和抗原及其应用

Country Status (7)

Country Link
US (2) US10174123B2 (zh)
EP (1) EP2682475B1 (zh)
JP (1) JP6084170B2 (zh)
KR (2) KR101797090B1 (zh)
CN (2) CN102251013A (zh)
BR (1) BR112013021350A2 (zh)
WO (1) WO2012113266A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
CN102653730A (zh) * 2012-04-18 2012-09-05 中国人民解放军第二军医大学 一种肝癌起始细胞及其分离方法与应用
ES2728305T3 (es) * 2013-04-29 2019-10-23 Ogd2 Pharma Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas
CN104634979A (zh) * 2013-11-15 2015-05-20 汕头大学 微生物细胞表面抗原的筛选与鉴定方法
FR3013847A1 (fr) * 2013-11-28 2015-05-29 Univ Lille Sciences Tech Nouveau biomarqueur du cancer de la prostate.
WO2017062604A1 (en) 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Therapeutic compounds and methods
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途
RU2019138032A (ru) 2017-05-26 2021-06-28 Новассэй Са Вспомогательная субъединица альфа-2-дельта потенциалзависимых кальциевых каналов и ее применения
WO2018233333A1 (zh) * 2017-06-23 2018-12-27 苏州博聚华生物医药科技有限公司 一种靶向人肿瘤干细胞的单克隆抗体及其应用
CN107474139B (zh) * 2017-06-23 2021-04-27 苏州博聚华生物医药科技有限公司 一种靶向人肿瘤干细胞的单克隆抗体及其应用
CN107163146B (zh) * 2017-06-23 2021-04-23 苏州博聚华生物医药科技有限公司 一种靶向人肿瘤干细胞的单克隆抗体及其应用
CN110878330B (zh) * 2019-12-17 2022-06-10 湖南农业大学 一种人胚肾细胞株在药物筛选中的应用
CN111304170B (zh) * 2019-12-17 2022-05-13 湖南农业大学 一种稳定共表达cacna2d1、grin1和grin2b的人胚肾细胞株及其构建方法
KR102466369B1 (ko) * 2020-08-04 2022-11-14 서울대학교병원 자가면역 뇌염의 진단 방법
JP7440905B2 (ja) * 2020-08-25 2024-02-29 株式会社オンチップ・バイオテクノロジーズ 粒子の純化方法、単一粒子分注方法、及び細胞クラスター解析方法、並びそれに用いる装置
CN114280303A (zh) * 2020-09-28 2022-04-05 天津市肿瘤医院（天津医科大学肿瘤医院） 一种检测肿瘤转移种子细胞的免疫组化染色试剂盒及其应用
CN113203858B (zh) * 2021-05-06 2021-12-07 潍坊三维生物工程集团有限公司 一种肿瘤检测试剂盒
CN114292918A (zh) * 2021-12-31 2022-04-08 刘飞 一种基于LncRNA546标志物的前列腺癌早期诊断方法
KR20240042301A (ko) * 2022-09-23 2024-04-02 동아대학교 산학협력단 방광암의 항암제 내성 진단용 바이오마커 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441156B1 (en) * 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
JP2003512602A (ja) * 1999-09-16 2003-04-02 ワーナー−ランバート・カンパニー α２δ−１サブユニット結合リガンドのスクリーニング方法
WO2003048321A2 (en) * 2001-12-03 2003-06-12 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP1615493A2 (en) * 2003-04-14 2006-01-18 Warner-Lambert Company LLC Non-human mammals and animal cells containing a mutated alpha2/delta1 gene
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
WO2006017293A2 (en) * 2004-07-13 2006-02-16 Regents Of The University Of California Models and methods for nociception, pain transduction, and screening for analgesic compounds
CN1873410B (zh) * 2005-06-16 2011-11-30 中国医学科学院肿瘤研究所 一种在食管癌病人血清中检测肿瘤相关标志物的方法
US8153369B2 (en) * 2006-06-05 2012-04-10 Cancer Care Ontario Assessment of risk for colorectal cancer
EP2192916A4 (en) 2007-08-23 2012-04-04 Univ Leland Stanford Junior MODULATION OF SYNAPTOGENESIS
EP2615115A3 (en) * 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
CN102251013A (zh) * 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用

Also Published As

Publication number Publication date
KR101885705B1 (ko) 2018-08-06
US10174123B2 (en) 2019-01-08
KR20140020922A (ko) 2014-02-19
JP2014507150A (ja) 2014-03-27
JP6084170B2 (ja) 2017-02-22
KR101797090B1 (ko) 2017-11-13
EP2682475A4 (en) 2015-01-14
US20200040097A1 (en) 2020-02-06
KR20170126033A (ko) 2017-11-15
EP2682475B1 (en) 2019-11-13
CN103562403A (zh) 2014-02-05
US20140044729A1 (en) 2014-02-13
WO2012113266A1 (zh) 2012-08-30
CN103562403B (zh) 2018-11-16
CN102251013A (zh) 2011-11-23
EP2682475A1 (en) 2014-01-08
BR112013021350A2 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
CN103562403A8 (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
PH12017501114A1 (en) Anti-c5 antibodies and methods of use
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
WO2011127412A3 (en) Soluble human st-2 antibodies and assays
WO2012145469A8 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
NZ607680A (en) Novel antigen binding proteins
EA201400875A1 (ru) Антитела к cd47 и способы их применения
WO2011139974A3 (en) Anti-pai-1 antibodies and methods of use thereof
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
NZ612394A (en) Tnf-α binding proteins
NZ594682A (en) Fully human antibodies specific to cadm1
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
WO2013004076A8 (zh) Agr2阻断抗体及其用途
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
MX2019004940A (es) Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
MX2018012473A (es) Agentes que reconocen el epitopo de clever-1 y usos de los mismos.
RU2017113732A (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)
WO2015161311A3 (en) Humanized anti-tf-antigen antibodies
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Biological Conservation Information

Correct: CGMCC 4416 2010.12.08

Number: 06

Volume: 30

Correction item: Biological Conservation Information

Correct: CGMCC 4416 2010.12.08

Number: 06

Page: The title page

Volume: 30

GR01 Patent grant
GR01 Patent grant